August 1, 2018
Kyowa Hakko Kirin is steadily pursuing its Nesp (darbepoetin alfa) authorized biosimilar (AB) program towards its approval, company executives said at earnings conference on July 31, but they disclosed none of its details, including its development and filing status. “At...read more